This is a standard long-term incentive grant with no immediate trading signal. Monitor FDA catalyst timelines for Viaskin Peanut — the PSU structure aligns CEO incentives with regulatory success, but the filing itself does not change the company's risk profile or valuation.
Price Chart
Executive Summary
DBV Technologies granted CEO Daniel Tass 4,060,000 performance share units (PSUs) tied to FDA approval of Viaskin Peanut BLA(s) by July 1, 2028. The award is a routine compensatory arrangement with no immediate financial impact — no departure, no financial data, and no change to the company's operations or outlook.
Key Facts
- CEO Daniel Tass received 4,060,000 PSUs under the newly approved 2026 Performance Share Unit Plan.
- Vesting requires FDA approval of Viaskin Peanut BLA(s) by July 1, 2028, plus continued employment.
- 2,900,000 PSUs vest on first FDA approval; 1,160,000 on second approval (or all if single BLA covers both age groups).
- Vested shares deliver in four equal installments from July 2028 through January 2030.
- No CEO departure, no financial results, no guidance, and no material agreement beyond the PSU grant.
Financial Impact
No financial figures reported; PSUs are contingent on future regulatory milestones with no current cash or earnings effect.
Risk Factors
- PSUs expire worthless if FDA approvals are not achieved by July 1, 2028.
- Potential dilution of ~4.06M ordinary shares upon vesting, though contingent on regulatory outcomes.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-259488 |
| Document: 0001193125-26-259488-index-headers.html | 0001193125-26-259488 |
| Document: 0001193125-26-259488-index.html | 0001193125-26-259488 |
| Document: 0001193125-26-259488.txt | 0001193125-26-259488 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 5, 2026 20w ago | 8-K | $4.26 $4.26 | · 0.00% | ▼ −1.41% | $1.98 (−53.52%) |
Apr 30, 2026 25w ago | 8-K | $4.26 $4.26 | · 0.00% | ▼ −5.27% | $1.98 (−53.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers